SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001664710-23-000036
Filing Date
2023-06-06
Accepted
2023-06-06 16:15:57
Documents
12
Period of Report
2023-06-06
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K kros-20230606.htm   iXBRL 8-K 50250
  Complete submission text file 0001664710-23-000036.txt   195544

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT kros-20230606.xsd EX-101.SCH 1899
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT kros-20230606_lab.xml EX-101.LAB 25848
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT kros-20230606_pre.xml EX-101.PRE 13579
6 EXTRACTED XBRL INSTANCE DOCUMENT kros-20230606_htm.xml XML 12259
Mailing Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421
Business Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421 617-314-6297
Keros Therapeutics, Inc. (Filer) CIK: 0001664710 (see all company filings)

IRS No.: 811173868 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39264 | Film No.: 23996280
SIC: 2834 Pharmaceutical Preparations